Yazar "Kaya, Eda" için listeleme
-
Association of metabolic dysfunction-associated fatty liver disease with cognitive impairment and all-cause dementia: A comprehensive review
Kaya, Eda; Yılmaz, Yusuf (AVES, 2024)Metabolic dysfunction-associated fatty liver disease (MAFLD) is a significant public health concern, affecting one-third of the global population and posing a risk for progressive liver disease. MAFLD is characterized by ... -
Changes in the etiology of chronic liver disease by referral to a FibroScan center: Increasing prevalence of the nonalcoholic fatty liver disease
Eriş, Tansu; Hassan, Moomen; Hikal, Yousra; Sawah, Enas; Daneshgar, Fatemeh; Teker, Ayşe Gülşen; Özel, Furkan; Lüleci, Nimet Emel; Kaya, Eda; Yılmaz, Yusuf (Kare Publishing, 2023)Background and Aim: Chronic liver disease (CLD) is a leading cause of morbidity and mortality worldwide with a wide etiological spectrum. Fi-broScan (R) is used for follow-up of fibrosis and steatosis. This single -cen-ter ... -
Deciphering the implications of MAFLD and MASLD definitions in the NAFLD population: Results from a single-center biopsy study
Kaya, Eda; Yılmaz, Yusuf (Wolters Kluwer Medknow Publications, 2024)To the Editor: The nomenclature for steatotic liver disease has been a topic of debate since 2020. The conventional expression, non-alcoholic fatty liver disease (NAFLD), was introduced in 1980 to describe the occurrence ... -
Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease
Kaya, Eda; Yılmaz, Yusuf (Sage Publications, 2022)Metabolic (dysfunction)-associated fatty liver disease (MAFLD) is the most common chronic liver disease worldwide – with an estimated global prevalence of 37%. Different from nonalcoholic fatty liver disease (NAFLD), which ... -
Noninvasive, serum-based evaluation of liver fibrosis in metabolic (dysfunction)-associated fatty liver disease
Kaya, Eda; Yılmaz, Yusuf (Elsevier, 2024)Advanced hepatic fibrosis is the most relevant prognostic factor in patients with metabolic (dysfunction)–associated fatty liver disease (MAFLD), being a significant predictor of both liver-related and all-cause mortality. ... -
The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
Yılmaz, Yusuf; Kaya, Eda (Kare Publishing, 2023)Among chronic liver conditions, metabolic (dysfunction)-associated fatty liver disease (MAFLD) ranks as the most frequent. With a worldwide prevalence of 37%, the global burden of MAFLD is large and growing.
